Teva Canada Innovation v. Pharmascience Inc., 2020 FC 1158
Jurisdiction | Federal Jurisdiction (Canada) |
Court | Federal Court (Canada) |
Citation | 2020 FC 1158 |
Date | 06 January 2021 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
9 practice notes
-
AbbVie Corporation v. Jamp Pharma Corporation, 2023 FC 1520
...A]The burden is on JAMP to prove each ground of invalidity on a balance of probabilities: Teva Canada Innovation v Pharmascience Inc, 2020 FC 1158 at para 156 A. General Principles of Claim Construction [143] The principles of claim construction are well-established. The Federal Court of Ap......
-
Allergan Inc. v. Apotex Inc., 2022 FC 260
...para 28; Teva Canada Limited v Janssen Inc, 2018 FC 754 at para 66, aff’d 2019 FCA 273; Teva Canada Innovation v Pharmascience Inc, 2020 FC 1158 at para 232). [147] There is an abundance of jurisprudence about the skilled person. [148] In Janssen Inc v Teva Canada Ltd, 2020 FC 593 at......
-
NCS Multistage Inc. v. Kobold Corporation, 2023 FC 1486
...for early disclosure of new and useful inventions: Wellcome Foundation at para 65. [205] In Teva Canada Innovation v Pharmascience Inc, 2020 FC 1158 at para 875, aff’d 2022 FCA 2 [Teva Canada Innovation], Justice Kane succinctly summarized the law for sound prediction. She reviewed t......
-
PHARMASCIENCE INC. v.TEVA CANADA INNOVATION, et al., 2022 FCA 2
...and 802 Patents. The three respondents are referred to hereinafter collectively as Teva. [2] In her decision running over 900 paragraphs (2020 FC 1158), Justice Kane (the Trial Judge) carefully reviewed the evidence and the issues and concluded that the 437 Patent would not be infringed (be......
Request a trial to view additional results
3 cases
-
Allergan Inc. v. Apotex Inc., 2022 FC 260
...para 28; Teva Canada Limited v Janssen Inc, 2018 FC 754 at para 66, aff’d 2019 FCA 273; Teva Canada Innovation v Pharmascience Inc, 2020 FC 1158 at para 232). [147] There is an abundance of jurisprudence about the skilled person. [148] In Janssen Inc v Teva Canada Ltd, 2020 FC 593 at......
-
PHARMASCIENCE INC. v.TEVA CANADA INNOVATION, et al., 2022 FCA 2
...and 802 Patents. The three respondents are referred to hereinafter collectively as Teva. [2] In her decision running over 900 paragraphs (2020 FC 1158), Justice Kane (the Trial Judge) carefully reviewed the evidence and the issues and concluded that the 437 Patent would not be infringed (be......
-
Google LLC v. Sonos, Inc., 2022 FC 1116
...amendment to Sonos’ pleading. [93] Google relies on Justice Kane’s decision in Teva Canada Innovation v Pharmascience Inc, 2020 FC 1158 [Teva]. [94] Specifically, Google relies on Justice Kane’s statement at paragraph 796, which it says is on all-fours with the current ......
4 firm's commentaries
-
FCA upholds patent validity, rejects argument that a soundly predicted invention must be obvious
...relevant. *** Links to decisions: Trial decision: Teva Canada Innovation v. Pharmascience Inc., 2020 FC 1158 Appeal decision: Pharmascience Inc. v Teva Canada Innovation et al., 2022 FCA 2 caf/decisions/en/item/518823/index.do">affirmed a decision of the Federal Court (FC) finding that a pa......
-
Federal Court Decision Regarding Glatiramer Acetate Finds One Patent Obvious And Another Valid And Infringed
...involving Teva's patents pertaining to the drug glatiramer acetate (Teva's COPAXONE and Pharmascience's GLATECT): Teva v Pharmascience, 2020 FC 1158. Justice Kane found Canadian Patent No. 2,702,437 (437 patent) invalid for obviousness while Canadian Patent No. 2,760,802 (802 patent) was fo......
-
Divided Success In PM(NOC) Actions Regarding Glatiramer Acetate
...and guide their prescriptions. The Court granted Teva's request for injunctive relief. *** Teva Canada Innovation v. Pharmascience Inc., 2020 FC 1158 About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial i......
-
"Potential" For Inconsistent Results Supports Staying Re-Examination Of MS Drug Patent
...in other cases where facts demonstrate the "risk" of an inconsistent result. Footnotes 1Teva Canada Innovation v. Pharmascience Inc., 2020 FC 1158. 2 Teva Canada Innovation v. Pharmascience Inc., 2020 FC The content of this article is intended to provide a general guide to the subject matt......